Unichem Laboratories Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: July 1, 2025, 10:47 am

Competitors of Unichem Laboratories Ltd

All Competitor Stocks of Unichem Laboratories Ltd

Quarterly Result

Last Updated: May 31, 2025, 7:26 am

Below is a detailed analysis of the quarterly data for Unichem Laboratories Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Sales, as of Mar 2025, the value is 587.00 Cr.. The value appears strong and on an upward trend. It has increased from 533.00 Cr. (Dec 2024) to 587.00 Cr., marking an increase of 54.00 Cr..
• For Expenses, as of Mar 2025, the value is 503.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 448.00 Cr. (Dec 2024) to 503.00 Cr., marking an increase of 55.00 Cr..
• For Operating Profit, as of Mar 2025, the value is 84.00 Cr.. The value appears to be declining and may need further review. It has decreased from 86.00 Cr. (Dec 2024) to 84.00 Cr., marking a decrease of 2.00 Cr..
• For OPM %, as of Mar 2025, the value is 14.00%. The value appears to be declining and may need further review. It has decreased from 16.00% (Dec 2024) to 14.00%, marking a decrease of 2.00%.
• For Other Income, as of Mar 2025, the value is 9.00 Cr.. The value appears to be declining and may need further review. It has decreased from 14.00 Cr. (Dec 2024) to 9.00 Cr., marking a decrease of 5.00 Cr..
• For Interest, as of Mar 2025, the value is 5.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 7.00 Cr. (Dec 2024) to 5.00 Cr., marking a decrease of 2.00 Cr..
• For Depreciation, as of Mar 2025, the value is 30.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 31.00 Cr. (Dec 2024) to 30.00 Cr., marking a decrease of 1.00 Cr..
• For Profit before tax, as of Mar 2025, the value is 58.00 Cr.. The value appears to be declining and may need further review. It has decreased from 62.00 Cr. (Dec 2024) to 58.00 Cr., marking a decrease of 4.00 Cr..
• For Tax %, as of Mar 2025, the value is 8.00%. The value appears to be increasing, which may not be favorable. It has increased from 6.00% (Dec 2024) to 8.00%, marking an increase of 2.00%.
• For Net Profit, as of Mar 2025, the value is 53.00 Cr.. The value appears to be declining and may need further review. It has decreased from 58.00 Cr. (Dec 2024) to 53.00 Cr., marking a decrease of 5.00 Cr..
• For EPS in Rs, as of Mar 2025, the value is 7.52. The value appears to be declining and may need further review. It has decreased from 8.22 (Dec 2024) to 7.52, marking a decrease of 0.70.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 3:37 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: June 16, 2025, 11:09 am

Below is a detailed analysis of the balance sheet data for Unichem Laboratories Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 14.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 14.00 Cr..
• For Reserves, as of Mar 2025, the value is 2,437.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,348.00 Cr. (Mar 2024) to 2,437.00 Cr., marking an increase of 89.00 Cr..
• For Borrowings, as of Mar 2025, the value is 460.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 248.00 Cr. (Mar 2024) to 460.00 Cr., marking an increase of 212.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 659.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 559.00 Cr. (Mar 2024) to 659.00 Cr., marking an increase of 100.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 3,569.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,169.00 Cr. (Mar 2024) to 3,569.00 Cr., marking an increase of 400.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 1,300.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,196.00 Cr. (Mar 2024) to 1,300.00 Cr., marking an increase of 104.00 Cr..
• For CWIP, as of Mar 2025, the value is 31.00 Cr.. The value appears to be declining and may need further review. It has decreased from 123.00 Cr. (Mar 2024) to 31.00 Cr., marking a decrease of 92.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 1.00 Cr..
• For Other Assets, as of Mar 2025, the value is 2,239.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,849.00 Cr. (Mar 2024) to 2,239.00 Cr., marking an increase of 390.00 Cr..
• For Total Assets, as of Mar 2025, the value is 3,569.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,169.00 Cr. (Mar 2024) to 3,569.00 Cr., marking an increase of 400.00 Cr..

Notably, the Reserves (2,437.00 Cr.) exceed the Borrowings (460.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Unichem Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 19.53. This value is within the healthy range. It has increased from -10.01 (Mar 24) to 19.53, marking an increase of 29.54.
• For Diluted EPS (Rs.), as of Mar 25, the value is 19.47. This value is within the healthy range. It has increased from -10.01 (Mar 24) to 19.47, marking an increase of 29.48.
• For Cash EPS (Rs.), as of Mar 25, the value is 37.23. This value is within the healthy range. It has increased from 6.07 (Mar 24) to 37.23, marking an increase of 31.16.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 348.10. It has increased from 335.54 (Mar 24) to 348.10, marking an increase of 12.56.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 348.10. It has increased from 335.54 (Mar 24) to 348.10, marking an increase of 12.56.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 299.85. It has increased from 242.15 (Mar 24) to 299.85, marking an increase of 57.70.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 42.64. This value is within the healthy range. It has increased from 18.73 (Mar 24) to 42.64, marking an increase of 23.91.
• For PBIT / Share (Rs.), as of Mar 25, the value is 24.95. This value is within the healthy range. It has increased from 2.64 (Mar 24) to 24.95, marking an increase of 22.31.
• For PBT / Share (Rs.), as of Mar 25, the value is 21.96. This value is within the healthy range. It has increased from -8.76 (Mar 24) to 21.96, marking an increase of 30.72.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 19.53. This value is within the healthy range. It has increased from -10.01 (Mar 24) to 19.53, marking an increase of 29.54.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 19.53. This value is within the healthy range. It has increased from -10.01 (Mar 24) to 19.53, marking an increase of 29.54.
• For PBDIT Margin (%), as of Mar 25, the value is 14.22. This value is within the healthy range. It has increased from 7.73 (Mar 24) to 14.22, marking an increase of 6.49.
• For PBIT Margin (%), as of Mar 25, the value is 8.31. This value is below the healthy minimum of 10. It has increased from 1.09 (Mar 24) to 8.31, marking an increase of 7.22.
• For PBT Margin (%), as of Mar 25, the value is 7.32. This value is below the healthy minimum of 10. It has increased from -3.61 (Mar 24) to 7.32, marking an increase of 10.93.
• For Net Profit Margin (%), as of Mar 25, the value is 6.51. This value is within the healthy range. It has increased from -4.13 (Mar 24) to 6.51, marking an increase of 10.64.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.51. This value is below the healthy minimum of 8. It has increased from -4.13 (Mar 24) to 6.51, marking an increase of 10.64.
• For Return on Networth / Equity (%), as of Mar 25, the value is 5.61. This value is below the healthy minimum of 15. It has increased from -2.98 (Mar 24) to 5.61, marking an increase of 8.59.
• For Return on Capital Employeed (%), as of Mar 25, the value is 6.81. This value is below the healthy minimum of 10. It has increased from 0.75 (Mar 24) to 6.81, marking an increase of 6.06.
• For Return On Assets (%), as of Mar 25, the value is 3.85. This value is below the healthy minimum of 5. It has increased from -2.22 (Mar 24) to 3.85, marking an increase of 6.07.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.17. This value is within the healthy range. It has increased from 0.09 (Mar 24) to 0.17, marking an increase of 0.08.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.62. It has increased from 0.53 (Mar 24) to 0.62, marking an increase of 0.09.
• For Current Ratio (X), as of Mar 25, the value is 2.05. This value is within the healthy range. It has decreased from 2.40 (Mar 24) to 2.05, marking a decrease of 0.35.
• For Quick Ratio (X), as of Mar 25, the value is 1.06. This value is within the healthy range. It has decreased from 1.40 (Mar 24) to 1.06, marking a decrease of 0.34.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.05. This value is below the healthy minimum of 4. It has decreased from 1.12 (Mar 24) to 1.05, marking a decrease of 0.07.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 14.27. This value is within the healthy range. It has increased from 5.82 (Mar 24) to 14.27, marking an increase of 8.45.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.54. This value is within the healthy range. It has increased from 0.43 (Mar 24) to 7.54, marking an increase of 7.11.
• For Enterprise Value (Cr.), as of Mar 25, the value is 5,189.65. It has increased from 3,504.16 (Mar 24) to 5,189.65, marking an increase of 1,685.49.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.46. This value is within the healthy range. It has increased from 2.06 (Mar 24) to 2.46, marking an increase of 0.40.
• For EV / EBITDA (X), as of Mar 25, the value is 17.29. This value exceeds the healthy maximum of 15. It has decreased from 26.58 (Mar 24) to 17.29, marking a decrease of 9.29.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.31. This value is within the healthy range. It has increased from 2.02 (Mar 24) to 2.31, marking an increase of 0.29.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Price / BV (X), as of Mar 25, the value is 1.99. This value is within the healthy range. It has increased from 1.46 (Mar 24) to 1.99, marking an increase of 0.53.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.31. This value is within the healthy range. It has increased from 2.02 (Mar 24) to 2.31, marking an increase of 0.29.
• For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from -0.02 (Mar 24) to 0.02, marking an increase of 0.04.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness